Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database
Tingxi Wu, Yang Zhang, Yanfeng Shi, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 11, pp. 965-975
Closed Access | Times Cited: 17

Showing 17 citing articles:

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 17
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Ana E. Espinosa De Ycaza, Juan P. Brito, Rozalina G. McCoy, et al.
Thyroid (2024)
Closed Access | Times Cited: 16
Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
Khalidah A. Alenzi, Deemah S. Alsuhaibani, Bader Batarfi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 9
Exploring the potential of pheophorbide A, a chlorophyll-derived compound in modulating GLUT for maintaining glucose homeostasis
Saptadipa Paul, A Pallavi, Nikhil R. Gandasi
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 7
Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)
Tingxi Wu, Yanfeng Shi, Bin Zhu, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 3, pp. 313-321
Closed Access | Times Cited: 13
Pharmacological treatment of obesity in adults in Norway 2004–2022
Paz Lopez‐Doriga Ruiz, Øystein Karlstad, Kjersti Nøkleby, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2102-2110
Open Access | Times Cited: 4
Adverse tumor events induced by ranitidine: an analysis based on the FAERS database
ManTing Liu, DongQiang Luo, JiaZhen Jiang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-13
Closed Access | Times Cited: 4
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
Liyuan Liu
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
EVALUATING BOWEL OBSTRUCTION and ILEUS EVENTS in PATIENTS on GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW and META-ANALYSIS
Lama Alfehaid, Majed Alyami, Sumaya N. Almohareb, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System
Toru Ogura, Chihiro Shiraishi
Clinical Drug Investigation (2023) Vol. 43, Iss. 2, pp. 129-140
Closed Access | Times Cited: 11
Physiology and pharmacology of effects of GLP-1 based therapies on gastric, biliary and intestinal motility
Ryan J. Jalleh, Chinmay S. Marathe, Christopher Rayner, et al.
Endocrinology (2024) Vol. 166, Iss. 1
Open Access | Times Cited: 2
Novel double-layered PLGA microparticles-dissolving microneedle (MPs-DMN) system for peptide drugs sustained release by transdermal delivery
Bo Xu, Han Liu, Guozhong Yang, et al.
International Journal of Pharmaceutics (2024), pp. 125128-125128
Closed Access | Times Cited: 2
Pancreatitis Associated With Teduglutide: A Disproportionality Analysis via the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Joyce H Gu, Zachary Sheingold, Mark Samarneh
Cureus (2024)
Open Access | Times Cited: 1
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Clare A. Kelly, Jennifer A. Sipos
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 1
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Yifan Hong, Kebin Cheng, Han Qu, et al.
Journal of Pharmaceutical Health Care and Sciences (2024) Vol. 10, Iss. 1
Open Access
Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System
Mehul Bhattacharyya, Larry E. Miller, Anna L. Miller, et al.
Cureus (2024)
Open Access
NARRATIVE OVERVIEW OF POSSIBLE PREVENTIVE MEASURES FOR DIFFERENTIATED THYROID CARCINOMAS.
María José Castro, Lucas Leite Cunha, Laura Sterian Ward
Heliyon (2024) Vol. 11, Iss. 1, pp. e41284-e41284
Open Access
Page 1

Scroll to top